Cancer neoantigens are novel peptides presented by cancer cells that arise from tumor-specific mutations. Unlike normal cellular proteins, these neoantigens are recognized as foreign by the immune system, making them promising targets for cancer immunotherapy. Neoantigen-based therapies, such as personalized cancer vaccines and adoptive T-cell transfer, aim to harness the body’s immune response to selectively attack tumor cells while sparing healthy tissue. Recent advances in genomics and bioinformatics have accelerated the identification and validation of neoantigens, paving the way for highly individualized treatments. These therapies hold potential for improved efficacy and reduced toxicity compared to traditional cancer treatments, marking a significant advancement in personalized oncology.
Title : A novel mRNA genomic technology for precision medicine, early cancer diagnosis, prognosis, treatment follow-up and cancer gene therapy
Rajvir Dahiya, University of California San Francisco, United States
Title : The future of pharmacogenetic polymorphism, pharmacogenomics and pharmamicrobiome in cancer treatment
Bene Ekine-Afolabi, University of East London, United Kingdom
Title : Biosensor-based detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Hospital care for cancer patients - safety, quality of care, education and respect for patient’s rights
Mariola Wioletta Borowska, Maria Sklodowska-Curie National Research Institute of Oncology, Poland
Title : Importin7 induces M2 macrophage and promotes the progress of colorectal cancer by regulating the nucleus translocation of GRP78
Changjiang Yang, Peking University People's Hospital, China
Title : Cancer-associated fibroblasts derived soluble CADM1 predicts response to neoadjuvant chemoimmunotherapy in lung cancer
Jian Li, Shanghai Jiaotong University, China